[Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
Patients with ovarian carcinoma stages III and IV were treated with cis-platin (P), adriamycin (A) and cyclophosphamide (C). The total rate of remission in group PC (n = 58) was 86% (CR = 55%), in group PA (n = 48) 65% (CR = 48%) and in group PAC (n = 43) 63% (CR 47%). The number of cycles administered were 8 in PA and PAC, and 5 in PC. Half of the patients survived 18 months (PA), 19 months (PAC) and 21 months (PC) without signs of progression with a survival time of 25 months (PA), 27 months (PAC) and 29 months (PC). In patients who had received primary PA therapy, secondary treatment with combined CPC was carried out. Rate of remission 56%. Treosulphan after PC resulted in 14% remissions, etoposid after CP (n = 38) 11 (29%) remissions.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012086:Reoperation
D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin
Chemotherapie des fortgeschrittenen Ovarialkarzinoms. Studien Göttingen-Hannover.